Kanada - Inggris - Health Canada

torrent pharmaceuticals limited - duloxetine (duloxetine hydrochloride) - capsule (delayed release) - 30mg - duloxetine (duloxetine hydrochloride) 30mg - selective serotonin and norepinephrine-reuptake inhibitors

Kanada - Inggris - Health Canada

torrent pharmaceuticals limited - duloxetine (duloxetine hydrochloride) - capsule (delayed release) - 60mg - duloxetine (duloxetine hydrochloride) 60mg - selective serotonin and norepinephrine-reuptake inhibitors

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

torrent australasia pty ltd - levetiracetam, quantity: 1000 mg - tablet, film coated - excipient ingredients: maize starch; sodium starch glycollate type a; silicon dioxide; povidone; purified talc; magnesium stearate; hypromellose; titanium dioxide; macrogol 400 - use in epileptic patients aged 4 years and older, initially as add-on therapy, in the treatment of partial onset seizures with or without secondary generalisation. monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. add-on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme). add-on therapy in the treatment of primary generalized tonic clonic (pgtc) seizures in adults and children from 4 years of age with idiopathic generalised epilepsy (ige).

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

torrent australasia pty ltd - levetiracetam, quantity: 500 mg - tablet, film coated - excipient ingredients: maize starch; sodium starch glycollate type a; silicon dioxide; povidone; purified talc; magnesium stearate; hypromellose; titanium dioxide; macrogol 400; iron oxide yellow - use in epileptic patients aged 4 years and older, initially as add-on therapy, in the treatment of partial onset seizures with or without secondary generalisation. monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. add-on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme). add-on therapy in the treatment of primary generalized tonic clonic (pgtc) seizures in adults and children from 4 years of age with idiopathic generalised epilepsy (ige).

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

torrent australasia pty ltd - levetiracetam, quantity: 250 mg - tablet, film coated - excipient ingredients: maize starch; sodium starch glycollate type a; silicon dioxide; povidone; purified talc; magnesium stearate; hypromellose; titanium dioxide; macrogol 400; indigo carmine - use in epileptic patients aged 4 years and older, initially as add-on therapy, in the treatment of partial onset seizures with or without secondary generalisation. monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. add-on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme). add-on therapy in the treatment of primary generalized tonic clonic (pgtc) seizures in adults and children from 4 years of age with idiopathic generalised epilepsy (ige).

Irlandia - Inggris - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - esomeprazole - tablets gastro-resistant - 20 milligram - proton pump inhibitors

Irlandia - Inggris - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - esomeprazole - tablets gastro-resistant - 40 milligram - proton pump inhibitors

Uni Eropa - Inggris - EMA (European Medicines Agency)

ipsen pharma - mecasermin - laron syndrome - pituitary and hypothalamic hormones and analogues - for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like-growth-factor-1 deficiency (primary igfd).severe primary igfd is defined by:height standard deviation score ≤ -3.0 and;basal insulin-like growth factor-1 (igf-1) levels below the 2.5th percentile for age and gender and;growth hormone (gh) sufficiency;exclusion of secondary forms of igf-1 deficiency, such as malnutrition, hypothyroidism, or chronic treatment with pharmacologic doses of anti-inflammatory steroids.severe primary igfd includes patients with mutations in the gh receptor (ghr), post-ghr signalling pathway, and igf-1 gene defects; they are not gh deficient, and therefore, they cannot be expected to respond adequately to exogenous gh treatment. it is recommended to confirm the diagnosis by conducting an igf-1 generation test.

Uni Eropa - Inggris - EMA (European Medicines Agency)

ipsen pharma - mecasermin - laron syndrome - pituitary and hypothalamic hormones and analogues - for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like-growth-factor-1 deficiency (primary igfd).severe primary igfd is defined by:height standard deviation score ≤ -3.0 and;basal insulin-like growth factor-1 (igf-1) levels below the 2.5th percentile for age and gender and;growth hormone (gh) sufficiency;exclusion of secondary forms of igf-1 deficiency, such as malnutrition, hypothyroidism, or chronic treatment with pharmacologic doses of anti-inflammatory steroids.severe primary igfd includes patients with mutations in the gh receptor (ghr), post-ghr signalling pathway, and igf-1 gene defects; they are not gh deficient, and therefore, they cannot be expected to respond adequately to exogenous gh treatment. it is recommended to confirm the diagnosis by conducting an igf-1 generation test.

Inggris - Inggris - MHRA (Medicines & Healthcare Products Regulatory Agency)

torrent pharma (uk) ltd - montelukast sodium - oral tablet - 10mg